Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06LEA
|
|||
| Former ID |
DNCL001794
|
|||
| Drug Name |
MER-102
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Phase 1 | [1] | |
| Company |
Merrion Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Antithrombin-III (ATIII) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Glypican 1 network | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Common Pathway of Fibrin Clot Formation | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Fondaparinux sodium. Drugs Today (Barc). 2002 Mar;38(3):185-94. | |||
| REF 2 | Clinical pipeline report, company report or official report of Merrion's GIPET technology. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.